Kindly Md, Inc. rose 1.60% in after-hours trading, with Cyclerion Therapeutics, Inc. announcing a strategic relaunch and licensing agreement with MIT to advance a Phase 2-ready program for treatment-resistant depression. This news aligns with the positive movement of the stock.
Comments
No comments yet